Search results

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation.

Tenpoint Therapeutics is a global, clinical-stage biotech company developing treatments to rejuvenate vision in the aging eye. Its pipeline includes treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.

Amphilix AG is a Basel-based biotech developing next-generation radioligand therapies using a proprietary 3D linker platform and small-molecule ligands. Its clinical-stage lead AMX-0053 targets a protein for colorectal cancer and is ready for First-in-Human imaging. The company seeks CHF 9m Seed.

Toxicology Consultant with >25 years of experience in the Biopharmaceutical Industry. I support Startup and Biotech Companies to advance their projects into the clinical phase. Get in touch to discuss your project when you have a shortage of nonclinical and toxicological expertise.

Oncodesign Services is a leading CRO specializing in drug discovery and preclinical services in (immuno-)oncology, autoimmune, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, and in vitro/in vivo pharmacology.

We identified a novel immuno-oncology target through bacterial metabolites that activate tumor-residing macrophages, triggering a potent anti-tumor response. By leveraging natural metabolic processes, we develop small molecule therapies to enhance the body’s native immune defense against cancer.

ACM Biosciences AG is a subsidiary of ACM Biolabs PTE Ltd. Singapore. Its purpose is to internationalise its development activities. It leads all clinical and regulatory activities of its pipeline programs and coordinates business development discussions with potential partners.

We are focusing on worldwide sourcing,distributing and custom manufacturing of fine chemicals, intermediates, ingredients, specialities, niche APIs and NCE’S since 1997.

Cellerys AG is a clinical stage biotechnology company, developing immune tolerance therapeutics for the treatment of multiple sclerosis (MS). Antigenic peptides identified from MS patients are coupled to autologous red blood cells which, when reinfused, restore immune tolerance. in 2021 the company entered a

Preclinical safety/toxicology and strategic regulatory consulting for biotech start-ups, with a focus on supporting prgrams from preclinical development to first-in-human trials.  

Alloy Therapeutics is a biotechnology ecosystem company democratizing access to tools, technologies, and services for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapy, and drug delivery.

EvlaBio is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a Therapeutic Monoclonal Antibody (mAb) targeting unphysiological FGFR4/FGF23 cardiac overdrive in the setting of chronic kidney disease (CKD).

MEDICE has always developed and produced medicinal products almost exclusively at the Iserlohn site and concentrates in the prescription area on CNS, renal medicine and dialysis medicine. Salmon Pharma is the Swiss subsidiary of MEDICE.

We are specialized in processes optimization and validation, GMP and ISO compliance aspects, quality systems, risk analysis, CE marking, equipment qualification, project management, etc.

Azafaros is a clinical-stage biotech company addressing rare genetic lysosomal storage disorders with oral small molecules, including nizubaglustat. Our focus is on developing disease-modifying therapies for patients with, among others, GM1 and GM2 gangliosidoses, and Niemann-Pick Type C disease.

AlphaMol is an AI-based bio-pharmaceutical company focusing on G protein-coupled receptor drug discovery. The co-founders of AlphaMol are leading scientists in the area of GPCRs. Many essential molecular mechanisms and biotechnology were invented by the members of AlphaMol.

PDC Therapeutics is a clinical-stage biotech start-up developing targeted Polymer-Drug Conjugate technologies with an optimal therapeutic index. The proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability.

Founded in 2018, Peptone specializes in novel therapeutics for Intrinsically Disordered Proteins (IDPs), linked to inflammatory diseases such as cancer. Their approach integrates biophysics, supercomputing, and machine learning, now advancing in their labs.

SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.

Thermo Fisher Scientific Lengnau is a state-of-the-art multi-purpose manufacturing facility for the production of biologics. It offers highly flexible biomanufacturing technologies, from development to large-scale production with single use and stainless steel equipment to meet our customer needs.

Tigen is a Swiss clinical stage biotech company developing cell therapies to cure cancer. A disruptive catalyst, combining a unique culture with a multidisciplinary set of world-class capabilities and a long-term perspective to accelerate access to novel T-cell therapies for patients and society.

iQone is a Swiss specialty pharma company for oncology, immunology and rare diseases. We commercialise innovative and biosimilar medicines with 7 marketed and 9 late-stage products. iQone can support partner products directly in the 5 major EU + CH markets, and indirectly in the rest of Europe. iQone Healthca

MedXCell is a Swiss biotech venture builder led by entrepreneurs and backed by private investors. MedXCell's portfolio includes pre-clinical companies CYTEA BIO and Soteria Bio.

Landmark BioVentures AG, founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company. LBV takes a unique model focused on lean operations, smart capital allocation, and diversified nexus of 8 companies developing 12 first-in-class therapeutics.

MPC Therapeutics is the leading biotech company developing Mitochondrial Pyruvate Carrier (MPC) targeted therapies. MPC is an extraordinary target that plays a key role in metabolism. We are committed to delivering novel treatments in cancer immunotherapy, kidney diseases and neurodegeneration.

We are a clinical-stage biotech company developing first-in-class small molecules to induce mitophagy, i.e. the process of replacing damaged mitochondria. We address age-related and chronic diseases including CNS disorders to treat cognitive impairment.

IDEOGEN Group is a family-owned Swiss pharmaceutical group, providing global access to specialty medicines for unmet medical needs. We specialize in the commercialization of specialty medicines in Europe with challenging and evolving healthcare dynamics.

Somagenetix is a spin-off from the University of Zurich leveraging scientific, clinical & commercial expertise to solve unmet medical needs. With our gene therapy platform, we aim at becoming a leading company with first & best-in-class treatments for phagocyte-related disorders.

Mosanna is committed to improving patient outcomes and quality of life in high unmet need diseases, carefully selecting innovative medicines for further development. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

Adoram is a UNIGE spinoff that is developing next-generation allosteric small molecule drugs targeting A2A receptors for cancer and inflammatory diseases, powered by a proprietary AI-enhanced GPCR discovery platform and in-house screening technologies for rapid, high-quality lead generation.

Aukera Therapeutics is a preclinical stage company developing the first RAPTOR inhibitors, a new approach to selectively modulate the proven target mTORC1. The lead program focuses on genetically-driven epilepsies such as TSC. Future use include age-related and neurodegenerative diseases.

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation.

Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.

Aspeya, owned by Philip Morris International, operates independently and utilizes Fertin Pharma's oral technology platform. Fertin Pharma, a wholly owned subsidiary of Aspeya, is a CDMO that develops and manufactures innovative oral and intra-oral delivery systems.

Biotech in the Autoimmune/Fibrosis Therapeutics Space.

Ymmunobio AG is a preclinical stage biotechnology company developing first in class assets for the treatment of solid tumors.

Lucerna Chem is one of the leading distributors for life science products in Switzerland, providing high quality reagents and kits from more than 70 suppliers for both research and diagnostics. We conveniently supply our customers with a variety of 4 Mio. products in simple domestic shipments.

Aurealis Therapeutics is a Swiss-Finnish cell and gene therapy platform company. Our multi-target scalable low COGS products, based on genetically engineered lactic acid bacteria, addresses unmet medical needs: Chronic wounds - diabetic foot ulcers, venous ulcers, pressure ulcers - deadly cancers - ovarian ca

CROss Alliance® is a Swiss CRO specialised in early clinical development. With more than 500 trials performed at CROSS phase I unit or in selected EU sites, we are experts in PK, bioequivalence, first in man, tolerability studies including cardiac safety and efficacy models in healthy volunteers.

Atopia Therapeutics is developing a revolutionary treatment for allergic diseases such as atopic dermatitis, allergic asthma, food allergies and hay fever based on the discovery that a bacterium present in the human stomach produces a protein that protects us from these diseases.

NovaGo Therapeutics focuses on two regeneration promoting therapeutics aimed at restoring nerve fibre connections in acute spinal cord injury(SCI) Ph1b clinical trial for SCI was started in Dec 2024 and successful finslaized. PoC studies planned to start mid 2026.

NXI Therapeutics is committed to creating tomorrow’s disruptive immunotherapies for T cell-mediated autoimmune diseases and transplantation by coronin 1 modulation. NXI’s unique approach enables an auto- & allo-selective immunomodulation that retains immunocompetence against infections and cancer.

ZETA is an end-to-end solution provider and innovation leader for pharma & biotech and specializes in the design, automation, and qualification of customer-specific systems for pharmaceutical manufacturing. ZETA is an EPCMv contractor, drives digtialization and develops decarbonization strategies.

TissueLabs is a Swiss biotech pioneering biofabrication, developing 3D bioprinters, tissue-specific hydrogels, and engineered tissues. Supporting research, drug testing, and regenerative medicine, its long-term vision is to create the first transplantable bioartificial heart.

InCephalo is a preclinical stage biotech company with a compartment locked (CLocked) technology. InCephalo is positioning itself as a CLocked Fc-Fusion Cytokine and antibody company. The company’s most advanced product at a proprietary IL-12 for local application of brain cancers.

therainnova AG provides strategic and operational regulatory affairs consulting for the biopharmaceutical industry in Europe. With expert leadership and a strong partner network, we offer end-to-end regulatory support, including due diligence, to maximize portfolio value.

Limula is a Life Science Tools company based in Lausanne, Switzerland. We combine cell therapy process development and precision engineering to offer a fully closed and automated platform for the production of CAR-T and other highly-personalised treatments.

Healiva’s Wound Care & Skin Diseases proprietary Platform Technology includes an end-to-end approach with enzyme technology and cell therapies for wound care and skin diseases. The platform can diversify into vitiligo management, skin regeneration or sports injury applications.

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies. We leverage our world-class protein engineering & conjugation platform to generate novel protein therapeutics for cancer and other indications. Bright Peak is located in Basel and San Diego.

Athebio develops ultra-stable biotherapeutics using proprietary Athebody® DARPin molecules with high affinity and specificity. We partner on radiotherapeutics, T cell engagers, targeted delivery (LNP/AAV/oligo) and affinity ligands, enabling breakthrough therapeutic strategies.

Zambon Biotech is part of the Zambon group, it is focused in growing the portfolio and pipeline of the Zambon group by entering into partnerships, acquiring assets and supporting their clinical development up to commercialization as well as licensing commercial stage assets.

Noema Pharma is a clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions.

A Swiss life science company, spin-off of UZH, developing personalized skin tissue therapy to treat skin defects and beyond.

EsoCap AG is developing a unique targeted delivery platform technology for the treatment of patients with diseases of the esophagus. EsoCap recently successfully completed the double-blind, randomised, placebo-controlled Phase II ACESO study in the lead indication eosinophilic esophagitis (EoE).

Labatec is a privately owned Swiss-based pharmaceutical company with more than 50 years of experience in delivering high quality products to the European and Emerging Markets. Covering both the hospital and retail sectors, we have a portfolio of over 65 products and a growing geographic footprint.

AMYRA is developing a unique enzyme combination for curative care of Celiac Disease and Non-Celiac Gluten Sensitivity (NCGS), which represent major public health issues. AMYRA’s products have the potential to establish the standard of care and majorly impact the lives of affected people.

Vaderis Therapeutics AG is a clinical stage biotech focusing on treatment of rare diseases caused by vascular malformations. The company was founded in 2019 in Basel, Switzerland, and closed a Series A investment of CHF 18.1 Mio in 2020, and a Series B investment of USD 152 million in August 2026.

Novochizol SA researches and develops applications of Novochizol, a unique chitosan nanoparticle technology that yields different carriers of small molecules, peptides, nucleic acids and proteins for sustained, localized delivery to any living tissue, with intracellular targeting potential.

Rhizen is Swiss HQ biotech focused on discovery & development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. The company has demonstrated leadership of the PI3K space and has a deep pipeline of novel differentiated assets across various stages of development.

GlycoEra is developing biologics to selectively degrade autoimmune disease causing circulating proteins rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies.

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland and abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.

MUVON is a Swiss, clinical stage biotech company with the goal of revolutionizing the treatment of diseases caused by muscle damage or degradation through the use of the patients' own cells. Our initial area of focus is the treatment of stress urinary incontinence in women (PhII completed).

Spin-off from EPFL developing precision gene therapies for Amyotrophic Lateral Sclerosis (ALS). ALS pathogenic mechanisms support that non-neuronal cells play a key role in this disease, through reshaping neuronal synaptic connections.

Parexel is focused on the development of innovative new therapies to improve the world’s health. We do this by providing a suite of groundbreaking biopharmaceutical development services that help customers across the globe transform scientific discoveries into new treatments for patients. From clinical tria

A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indications in IBD, dysbiosis induced by antibiotic treatments and unhealthy diet, and as enhancer in cancer immunotherapy.

Centenara is an integrated biotechnology platform company that develops and improves therapies and technologies to promote healthy aging and prolong lifespan. We provide start-up coaching and funding to entrepreneurial scientists to co-create therapies that benefit our aging population.

Gut-restricted metabolic therapies. Validated platform with 3 preclinical proof-of-concepts. Established as a private company (AG) in Basel in 2019. Secured a partnership with Nestlé Health Science for one asset. Raised CHF 10M in equity and non-dilutive funding. Raising Series A.

GliaPharm is a Swiss biotechnology company developing treatments for neurological disorders. The company has developed a proprietary platform and pipeline of molecules targeting brain glial cells to restore brain metabolism deficits in neurological diseases linked to brain metabolism dysfunction.

Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications. We are rapidly advancing our pipeline of antibodies and antibody-drug conjugates through clinical development.

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases.

SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.

Synendos is a clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric and neurological disorders through the modulation of a new drug target in the endocannabinoid system enabling restoration of the natural functioning of the brain.

Orion Biotechnology is a Swiss/Canadian clinical stage company. Orion is the only company with a novel approach to drug peptide and protein GPCRs. Our platform offers one of the fastest drug discovery solutions in industry to target peptidergic GPCRs. Orion has a strong and diverse pipeline.

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.

Clinical-stage biotech company developing next-generation allosteric therapies. Its candidate, GT-02287, is in P1b trials for PD with potential in other neurodegenerative and lysosomal storage disorders. The pipeline also includes preclinical programs targeting metabolic diseases and solid tumors.

SunRegen is a biopharmaceutical company with a mission to develop drugs to treat neurodegenerative diseases.

Selective mode antimicrobial resistance therapeutics Selmod is a startup with a mission dedicated to the development of disruptive antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance. Focus on high revenue segment - patients in hospitals.

IPS Biopharma AG is tackling one of the biggest challenges in cancer treatment: recurrence. Our phase 2 asset, IP‑001, can activate specific anti-tumor immunity following in situ tumor destruction, turning standard focal interventions into a potential catalyst for durable anti-cancer immunity.

We provide our clients, however complex their challenges may be, with effective and high quality solutions throughout the life cycle of their products and the evolution of their company.

HAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer.

Swiss-based Life Sciences consultancy and part of the athagoras Group. We enable European market access for pharma & biotech, combining strategy, evidence generation and HTA expertise, from valuation and trial design to reimbursement, JSC, JCA and pricing negotiations.

iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families.

Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.

TOLREMO engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies.

At UCB, we are inspired by patients and driven by science. Our strategy: to offer value to people suffering from severe diseases in neurology and immunology. In Switzerland, UCB invested around 800 million CHF in his plant for industrial equipment on the cutting edge of technology and innovation.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.